Comparative Pharmacology
Head-to-head clinical analysis: DOLENE versus DSUVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLENE versus DSUVIA.
DOLENE vs DSUVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
Selective, high-affinity agonist at the mu-opioid receptor, resulting in analgesia via activation of G-protein coupled inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels in the central nervous system.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
30 mcg sublingual tablet as a single dose; may repeat once after 1 hour if needed. Maximum 2 doses per 24 hours.
None Documented
None Documented
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Terminal elimination half-life is approximately 23.4 hours (range 17–30 h), supporting once-daily dosing. Due to rapid redistribution, clinical effects may wane before elimination is complete.
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Primarily renal elimination of metabolites; unchanged drug accounts for <1% of the dose. Fecal excretion is minimal. Total recovery: ~70% in urine, ~20% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic